Provided by Tiger Trade Technology Pte. Ltd.

Organon & Co

6.03
-0.2400-3.83%
Post-market: 6.070.0400+0.66%19:32 EDT
Volume:6.34M
Turnover:38.49M
Market Cap:1.57B
PE:8.38
High:6.30
Open:6.29
Low:6.02
Close:6.27
52wk High:15.85
52wk Low:6.02
Shares:259.98M
Float Shares:258.73M
Volume Ratio:2.09
T/O Rate:2.45%
Dividend:0.08
Dividend Rate:1.33%
EPS(TTM):0.7200
EPS(LYR):0.7200
ROE:30.56%
ROA:6.22%
PB:2.08
PE(LYR):8.38

Loading ...

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Reuters
·
13 hours ago

KDventures to write down remaining Forendo earnout value after Organon halts PCOS drug development

Reuters
·
Mar 03

KDventures to write off remaining Forendo earnout book value

Reuters
·
Mar 03

Organon's Breast Cancer Treatment Poherdy Receives Positive Opinion from EMA Panel

MT Newswires Live
·
Feb 27

Organon reports Phase 3 analysis showing VTAMA improves sleep in children with atopic dermatitis

Reuters
·
Feb 27

Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth

TIPRANKS
·
Feb 26

Organon posts FY 2025 Emgality sales of USD 174 million up 63%

Reuters
·
Feb 25

Organon Is Maintained at Underweight by Barclays

Dow Jones
·
Feb 24

Organon price target raised to $8 from $7.50 at Barclays

TIPRANKS
·
Feb 24

Barclays Remains a Sell on Organon (OGN)

TIPRANKS
·
Feb 24

Organon to exclusively license global rights to Miudella for $27.5M

TIPRANKS
·
Feb 23

BRIEF-Organon Enters Into Agreement To License Miudella®

Reuters
·
Feb 23

Organon Licenses Global Rights to Sebela’s MIUDELLA Copper IUD

Reuters
·
Feb 23

Organon Enters Into Agreement to License Miudella®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

THOMSON REUTERS
·
Feb 23

Organon & Co - Co to Pay $27.5 Mln With up to $505 Mln in Milestones

THOMSON REUTERS
·
Feb 23

Organon Shares Rise 1.7% After Independent Review Finds There Are No Issues in Past Biosimilar Purchases

THOMSON REUTERS
·
Feb 20

BUZZ-Organon rises as review finds no issues in past biosimilar purchases

Reuters
·
Feb 20

Organon & Co: Independent Review Did Not Find Evidence of Improper Conduct Related to Timing of Purchases of Biosimilars From Supplier in Prior Years

THOMSON REUTERS
·
Feb 20

Organon Audit Committee Clears Biosimilar Purchase Timing Review

Reuters
·
Feb 20

Morgan Stanley Keeps Their Hold Rating on Organon (OGN)

TIPRANKS
·
Feb 17